BIIB080 is an antisense oligonucleotide therapy designed to target microtubule-associated protein tau mRNA and reduce the production of tau.

As a consequence, PNAs are emerging as versatile tools in molecular biology, with applications spanning diagnostics, gene editing, antisense therapy, and the assembly of nanostructures.

Intratumoral Epidermal Growth Factor Receptor Antisense DNA Therapy in Head and Neck Cancer: First Human Application and Potential Antitumor Mechanisms ...

Antisense therapy is an innovative, commercially-validated therapeutic approach, but often requires frequent administration or the delivery of large doses to achieve uptake at the intended site of ...

TMDU researchers demonstrate proof of concept of antisense nucleic acid therapy to prevent the spread of α-synuclein pathologies in synucleinopathies.

Antisense therapy is a type of treatment that uses antisense oligonucleotides to target messenger RNA (mRNA).

Oligonucleotides are short, single-stranded DNA or RNA molecules that play a crucial role in various biotechnological applications, including PCR, hybridization assays, antisense therapy, and gene ...

Treading a low-risk path, Australia-based Antisense Therapeutics in-licenses second-generation leads from Isis Pharmaceuticals and out-licenses products to larger companies.

Dawnzera is the first and so far only RNA-targeting therapy approved as a prophylactic treatment for hereditary angioedema ...

BIIB080 is an antisense oligonucleotide therapy designed to target microtubule-associated protein tau mRNA and reduce the production of tau.